sábado, 24 de diciembre de 2022

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma | FDA

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma | FDA

No hay comentarios:

Publicar un comentario